AzTrials
AzTrials

Acute Mountain SicknessPhase 1SEAWARDNCT03424226

Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages

A Phase 1 study testing Acetazolamide in people with Acute Mountain Sickness, run by Stanford University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This double blind randomized trial will compare acetazolamide taken the morning of ascent to acetazolamide taken the evening prior to ascent for the prevention of acute mountain sickness (AMS). The day of ascent dosing has not been studied as a powered primary outcome. Read more about this study

Who is it for?
Ages 18 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Acute Mountain Sickness
What is being tested?
Acetazolamide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
105 participants
Where
1 siteUnited States
Study dates
4 Aug 2018to 30 Sep 2018
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age 18-75 healthy non-pregnant volunteer
  • live at low elevation < 4000 ft
  • Arrange your own transportation to WMRS (Bishop) by Friday evening of study weekend
  • Available for full study duration (Friday PM-Sunday AM)

Who cannot join

  • Age <18 or >75, Pregnant, Live at altitude >4000 ft Slept at altitude > 4000ft within 1 week of study Allergic to acetazolamide, sulfa drugs, Taking non-steroidal anti-inflammatory drugs, Acetazolamide, or Corticosteroids 1 week prior to study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Stanford University

    Stanford, California, 94305

Other trials in United States

About this study

This double blind randomized trial will compare acetazolamide taken the morning of ascent to acetazolamide taken the evening prior to ascent for the prevention of acute mountain sickness (AMS). The day of ascent dosing has not been studied as a powered primary outcome. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California

Read the detailed description

The specific aim of this study is to determine whether acetazolamide started the day-of ascent is inferior to the standard night before ascent dose of acetazolamide for the prevention of acute mountain sickness (AMS) in travelers in travelers to high altitude. Acetazolamide has been examined in over 200 high altitude studies over the past 50 years, and is the most commonly used drug for AMS prevention in the high mountains of Nepal, Western Europe, and Africa. Current Wilderness Medical Society Practice Guidelines recommend a 125mg dose of acetazolamide daily started the day or evening prior to ascent. However, day of ascent dosage has recently been found to be effective prophylaxis for severe AMS compared to placebo, but efficacy of day-of ascent dosage has not be confirmed versus standard acetazolamide dosage.

While acetazolamide is commonly used as an acclimatization aid, it is traditionally started the day or evening prior to ascent to theoretically optimize diuretic effect and compensatory respiratory changes. This timing may be impractical when rapid ascent is necessary, such as in search and rescue and military operations, or for the general recreationalists, trekkers, or climbers who do not have time to start prophylaxis prior to heading into the mountains. As there are an estimated 100 million recreationalists annually who ascend to high altitude around the world, innovation on optimal timing has a potentially large impact on traveler safety.

Acetazolamide has a time of onset between 60 - 90 minutes when taken as an immediate release tablet, with peak effect between 2 - 4 hours. With these pharmacokinetics in mind, we recently found that there was an observed robust protective effect of acetazolamide on severe AMS when taken the morning of ascent, and this was the first study to examine day-of dosing. This novel finding has not been otherwise investigated, and confirmation of this unique observation has the potential to increase acetazolamide'sits usage in "high risk" populations maximizing safety, while minimizing discomfort and poor sleep from pre-ascent nocturia., such as trekkers, skiers, climbers, and tactical missions requiring rapid ascents in the mountains of North America and Europe.

Being tested
Acetazolamide
Medical subject headings
Altitude Sickness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AcetazolamideDrug

    Also called diamox

    a diuretic and commonly used medication for prevention and treatment of acute mountain sickness

Study groups in NCT03424226
Study groupRoleWhat they receive
day of acetazolamideExperimentalacetazolamide 125mg twice a day, started morning of ascent
Receives: Drug: Acetazolamide
night before acetazolamideActive comparatoracetazolamide 125mg twice a day, started evening before ascent
Receives: Drug: Acetazolamide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. incidence of acute mountain sickness

    incidence of acute mountain sickness by Lake Louise Questionnaire

    Measured: 2 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Feb 2018
  2. Study start4 Aug 2018
  3. Primary completion30 Sep 2018
  4. Study completion30 Sep 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double blind randomized controlled trial
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
105 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03424226
Sponsor's protocol ID
44765
Acronym
SEAWARD
Status last verified
Nov 2018
First submitted
31 Jan 2018
Last updated
20 Nov 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Acetazolamide in people with Acute Mountain Sickness, run by Stanford University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

incidence of acute mountain sickness (time frame: 2 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in